Alnylam cuts 2026 sales forecast, shares drop over 28%, investors face potential losses

Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower growth after initial demand in the ATTR-CM market. This announcement led to a sharp drop in its stock price by more than 28%, causing significant losses for investors. A law firm is investigating possible securities law violations and is offering legal help to affected investors. This development highlights risks in biotech launches and potential legal recourse for shareholders.